Episode 37 - Dr. Dave Miller and the Evolution of Drug Delivery Technologies
My Guest in this episode is Dr. Dave Miller. Dave is CSO of AustinPx and leads the pharmaceutics and analytical development teams and oversees the application of the KinetiSol™ Technology. Prior to his current position, Dr. Miller served as Vice President of Research and Development at DisperSol Technologies and Senior Principal Scientist at Hoffmann-La Roche. Dr. Miller is a co-inventor of the pharmaceutical applications of the KinetiSol technology. He has published over 40 research articles in peer-reviewed journals, authored 8 book chapters, and is co-editor of the First, Second, and Third Editions of the textbook, Formulating Poorly Water-Soluble Drugs. He is a co-inventor on numerous granted and pending patents worldwide. Dr. Miller holds a B.S. in Chemical Engineering and a Ph.D. in Pharmaceutics from the University of Texas at Austin. In this conversation, Dave shares his extensive journey in pharmaceutical research and development, highlighting the evolution of drug delivery technologies, particularly Kinetisol. He discusses the challenges of transitioning from R&D to commercialization, the importance of precision medicine, and the complexities of manufacturing in the pharmaceutical industry. Dave emphasizes the need for innovative approaches to drug formulation and the role of emotional intelligence in professional success. I enjoyed my chat with Dr. Dave Miller. Hope you do too. Here's Dr. Dave Miller.
--------
47:43
--------
47:43
Episode 36 - Brandon Rice and IND Submission with AI
My guest in this episode is Brandon Rice. Brandon is the CEO and co-founder at Weave Bio, a software company focused on automating regulatory submissions in the pharmaceutical industry using AI where he oversees product development, specifically leading the creation of AutoIND, their AI-powered platform for IND preparation. In this conversation, Brandon discusses his journey to co-founding Weave Bio. He highlights the challenges of regulatory compliance, the potential of AI to streamline processes, and the importance of human oversight in AI-generated content. The discussion also touches on the cultural differences in AI adoption among pharmaceutical companies, global regulatory trends, and the need for open-mindedness towards new technologies. I thoroughly enjoyed my chat with Brandon and learned a lot about the current AI in pharma landscape. I hope you do too. Here's Brandon Rice.
--------
34:47
--------
34:47
Episode 35 - Nikkhil Masurkar and How American Healthcare and Indian Pharma Are Connected
My guest in this episode is Nikkhil Masurkar. Nikkhil is the CEO of Entod Pharmaceuticals which is based in India. He is often called India’s Eye Drops Man because Entod specializes in ophthalmic, ENT, and dermatological medicines. In this interview, Nikkil and I talked about how closely American and Indian pharma worlds are intertwined - 4 out of 10 prescriptions filled in the U.S. are supplied by Indian companies. They supply almost half of all generic prescriptions. This translates to a significant cost savings for the U.S. healthcare system - over $1.3 trillion in last 10 years alone. We also talked about - Why India is considered the 'Pharmacy of the World' - How Indian pharma companies can move beyond generics into high-value innovation - How Indian pharma can be a $450 billion industry by 2047 - How to balance affordability with innovation to ensure life-saving drugs reach more people - The biggest regulatory hurdles Indian pharma companies face when expanding in the USA And what all of it means for the American healthcare system, American pharma industry, and American patients. We also discussed important leadership lessons, one thing about the Indian pharma industry Nikkhil would change if he could, and what he reads, instead of books, that drives his personal outlook and Entod Pharmaceutical's culture. I enjoyed my discussion with Nikkhil about how closely American and Indian pharma industries are connected. I hope you do too. Here's Nikkil Masurkar.
--------
36:56
--------
36:56
Episode 34 - Arielle Smith and How to Get the Most Out of the Pharma Conferences
My guest in this episode is Arielle Smith. Arielle serves as the President of Life Science at Event Cadence which is an event management platform. She was also one of the founding members of Event Cadence. It enables Life Science companies to efficiently plan and manage both industry conferences and internal meetings. Arielle has worked with pharma companies such as Merck, AstraZeneca, Jazz Pharma, Sanofi, and more. Previously, she has worked with Lampire Biological Laboratories and Jefferson Health, which helped her to provide the Healthcare industry with the best all-in-one industry conference solution. She also worked in sales and client management for Paramount-owned Showtime Networks, the company behind award-winning shows like Shameless and Billions. In this discussion, Arielle and I talk about - How to coordinate efforts of multiple team members - How to collect and leverage data for networking and meetings - The logistics of sending multiple employees to industry events - Individual attendees vs a group of employees being sent by companies. This was an interesting chat as it was about the logistics of attending industry events rather than what's being presented at those events. I found my discussion with Arielle very informative and timely considering the kickoff of industry events. I hope you do too. Here's Arielle Smith.
--------
37:12
--------
37:12
Episode 33 - Ray Jordan and Pharmaceutical Industry's Reputation and Image
My guest in this episode is Ray Jordan. Ray is Principal at Putnam Insights. Ray Jordan is a corporate affairs leader and reputational growth driver in healthcare, technology, biotechnology and consumer industries and has worked with or for companies such as Moderna, Amgen, Johnson & Johnson and Pfizer. Ray has been recognized numerous times by industry sources such as PRWeek, and PRovoke Media. He has helped companies get recognized for high reputational status, including in such rankings by FORTUNE, Axios/Harris, Science Magazine, Dow Jones and others. In this candid interview about the pharmaceutical industry's image and reputation, Ray and I talk about: - What an image crisis looks like from a leader's point of view. - The current pharma reputation landscape and the Gallup poll. - Pharma industry wide efforts to address this. - Difference between big and small pharma reputation needs and - The relationship between reputation and market cap. If you're interested in how corporations, particularly pharma companies, manage their public image, reputation, and any public issues, this episode is for you. Here's Ray Jordan.
The Future of Pharma with ISPE Boston.
Find out where the pharmaceutical industry is headed and what it means for you. Join host Samir Gondalia as he chats with the thought leaders of the pharma world about the new technologies, innovative applications and emerging markets and how it’s going to influence the future of Pharma.
New Zealand